First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Curr Pharm Des. 2013;19(17):3115-23. doi: 10.2174/1381612811319170019.
Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
他汀类药物治疗是初级和二级心血管预防策略的重要组成部分。然而，一部分患者即使使用最高耐受剂量的强效他汀类药物也无法达到低密度脂蛋白胆固醇（LDL-C）目标，或者不能耐受他汀类药物。对于这些患者，有几种治疗选择。考来烯胺是一种相对较新的胆汁酸螯合剂，可降低血清 LDL-C 水平。此外，考来烯胺可改善血糖控制，且至少在短期研究中耐受性良好。因此，对于不能通过强效他汀类药物单药治疗达到 LDL-C 目标的高危患者，考来烯胺似乎是一种有用的治疗工具。
